Miltefosine reduces the cytolytic activity and virulence of Acinetobacter baumannii [Experimental Therapeutics]

Stagnation in antimicrobial development has led to a serious threat to public health in which some Acinetobacter baumannii infections have become untreatable. New therapeutics with alternative mechanisms of action to combat A. baumannii are therefore necessary to treat these infections. To this end, the virulence of A. baumannii isolates with varying antimicrobial susceptibilities was assessed when treated with miltefosine, a phospholipase C inhibitor. Phospholipase C activity is a contributor to A. baumannii virulence associated with hemolysis, cytolysis of A549 human alveolar epithelial cells and increased mortality in the Galleria mellonella experimental infection model. While the effects on bacterial growth were variable amongst strains, miltefosine treatment significantly reduced both the hemolytic and cytolytic activity of all treated A. baumannii strains. Additionally, scanning electron microscopy of polarized A549 cells infected with bacteria of the A. baumannii ATCC 19606^T strain or the AB5075 multidrug resistant isolate showed decrease in A549 cell damage with a concomitant increase in the presence of A549 surfactant upon administration of miltefosine. The therapeutic ability of miltefosine is further supported by the results of G. mellonella infections wherein miltefosine treatment of animals infected with ATCC 19606^T significantly decreased mortality. These data demonstrate that inhibition of phospholipase C activity results in the overall reduction of A. baumannii virulence in both in vitro and in vivo models making miltefosine a viable option for treatment of A. baumannii infections, particularly those caused by multidrug resistant isolates.

https://ift.tt/2qe8CGW